Skip to main content
Log in

MGMT promoter methylation status in anaplastic meningiomas

  • Letter to the Editor
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Perry A, Louis DN, Scheithauer BW, Budka H, von Deimling A (2007) Meningiomas. In: Louis D, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system. IARC, Lyon, pp 164–172

    Google Scholar 

  2. Modha A, Gutin PH (2005) Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 57:538–550

    Article  PubMed  Google Scholar 

  3. Stupp R, Hegi ME, Gilbert MR, Chakravarti A (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136

    Article  CAS  PubMed  Google Scholar 

  4. de Robles P, McIntyre J, Kalra S, Roldan G, Cairncross G, Forsyth P, Magliocco T, Hamilton M, Easaw J (2008) Methylation status of MGMT gene promoter in meningiomas. Cancer Genet Cytogenet 187:25–27

    Article  PubMed  Google Scholar 

  5. Bello MJ, Aminoso C, Lopez-Marin I, Arjona D, Gonzalez-Gomez P, Alonso ME, Lomas J, de Campos JM, Kusak ME, Vaquero J, Isla A, Gutierrez M, Sarasa JL, Rey JA (2004) DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol 108:413–421

    Article  CAS  PubMed  Google Scholar 

  6. Chamberlain MC, Tsao-Wei DD, Groshen S (2004) Temozolomide for treatment-resistant recurrent meningioma. Neurology 62:1210–1212

    CAS  PubMed  Google Scholar 

  7. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P, Beier CP (2008) Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68:5706–5715

    Article  CAS  PubMed  Google Scholar 

  8. Hasselblatt M, Mühlisch J, Wrede B, Kallinger B, Jeibmann A, Peters O, Kutluk T, Wolff JE, Paulus W, Frühwald MC (2009) Aberrant MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation in choroid plexus tumors. J Neurooncol 91:151–155

    Article  CAS  PubMed  Google Scholar 

  9. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39–51

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Martin Hasselblatt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brokinkel, B., Fischer, B.R., Peetz-Dienhart, S. et al. MGMT promoter methylation status in anaplastic meningiomas. J Neurooncol 100, 489–490 (2010). https://doi.org/10.1007/s11060-010-0202-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0202-0

Keywords

Navigation